AbCellera Biologics Inc (ABCL) stock is currently valued at $4.2. During the last session, the stock experienced a remarkable rise, reaching $17.0 after opening at $4.16. The stock briefly dropped to $5.0 before ultimately closing at $4.36.
The market performance of AbCellera Biologics Inc’s stock has been harmonious in recent times.
52-week price history of ABCL Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. AbCellera Biologics Inc’s current trading price is -27.75% away from its 52-week high, while its distance from the 52-week low is 122.42%. The stock’s price range during the 52-week period has remained between $1.89 and $5.82. In the Healthcare sector, the company’s shares saw a trading volume of around 1.88 million for the day, which was evidently lower than the average daily volume of 6.17 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
AbCellera Biologics Inc (ABCL) has experienced a quarterly rise of 107.14% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.26B and boasts a workforce of 596 employees.
A Closer Look at Analysts’ Ratings for AbCellera Biologics Inc
As of right now, 7 analysts are rating AbCellera Biologics Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.96, with a change in price of +1.86. Similarly, AbCellera Biologics Inc recorded 5,316,370 in trading volume during the last 100 days, posting a change of +77.29%.
Examining ABCL’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for ABCL stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.06.
ABCL Stock Stochastic Average
As of today, AbCellera Biologics Inc’s raw stochastic average for the last 50 days stands at 59.35%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 19.74%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 23.50% and 26.07%, respectively.
ABCL Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Until today this year the stock’s price performance recorded an increase of 44.01%. However, over the last six months, the performance has been weaker by 31.00%. The price of ABCL increased 8.10% over the last 30 days. And in the last five days, it has fallen by -7.99%.
